Correlation between choroidal structure and smoking in eyes with central serous chorioretinopathy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
12
2020
accepted:
10
03
2021
entrez:
23
3
2021
pubmed:
24
3
2021
medline:
16
10
2021
Statut:
epublish
Résumé
A smoking habit can cause various health problems encompassing retinal diseases including central serous chorioretinopathy (CSC). The aim of the current study was to investigate the effect of smoking on the choroidal structure in patients with CSC. The choroidal vascular index (CVI) was calculated using the binarized OCT images. Baseline parameters (age, refractive error [SE], subfoveal choroidal thickness [SFCT] and CVI) were compared between smokers and non-smokers using Wilcoxon rank sum test. Moreover, the associations between SFCT and the baseline parameters were analyzed using a multivariate linear regression followed by the AICc model selection. Among 75 CSC patients, 45 patients were smokers and 30 patients were non-smokers. No significant differences in age and SE were seen between the smoking group and the non-smoking group. A significant difference in the SFCT was seen between two groups (382.0 ± 68.2 μm in the smoking group vs. 339.3 ± 52.3 μm in the non-smoking group, p = 0.0038), while no significant difference was observed in the CVI (p = 0.32). The optimal model for SFCT included the variables of age, SE and past history of smoking among the baseline parameters. Additionally, increased pack years was associated with increased SFCT. Cigarette smoking was associated with an increased SFCT in patients with CSC. Thicker choroid in smoking CSC patients may be an important modulator of the disease.
Identifiants
pubmed: 33755707
doi: 10.1371/journal.pone.0249073
pii: PONE-D-20-39783
pmc: PMC7987178
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249073Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Ophthalmol. 2006 Jul;124(7):995-1001
pubmed: 16832023
Cutan Ocul Toxicol. 2014 Jun;33(2):115-9
pubmed: 23841829
Am J Ophthalmol. 2008 Oct;146(4):496-500
pubmed: 18639219
Eye (Lond). 2013 Mar;27(3):387-91
pubmed: 23288136
Arch Ophthalmol. 1994 Aug;112(8):1057-62
pubmed: 8053819
J Ophthalmic Vis Res. 2019 Apr-Jun;14(2):164-170
pubmed: 31114653
Ophthalmologica. 2014;232(2):65-76
pubmed: 24776999
Am J Ophthalmol. 2015 Jul;160(1):72-84.e1
pubmed: 25887629
BMC Ophthalmol. 2010 Dec 13;10:31
pubmed: 21144031
Eye (Lond). 2011 Dec;25(12):1635-40
pubmed: 22020172
Prog Retin Eye Res. 2016 May;52:130-55
pubmed: 26478514
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):261-6
pubmed: 22167095
PLoS One. 2019 Feb 14;14(2):e0212055
pubmed: 30763369
Ophthalmology. 2012 Aug;119(8):1666-78
pubmed: 22521082
Retina. 1999;19(6):508-12
pubmed: 10606450
Retina. 2011 Sep;31(8):1603-8
pubmed: 21487334
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1316-1320
pubmed: 30943279
Retina. 1994;14(3):231-42
pubmed: 7973118
Br J Ophthalmol. 2019 Jun;103(6):725-729
pubmed: 30002072
Sci Rep. 2016 Feb 12;6:21090
pubmed: 26868048
Clin Chest Med. 1991 Dec;12(4):631-42
pubmed: 1747982
Clin Exp Ophthalmol. 2019 Jul;47(5):631-637
pubmed: 30663190
Retina. 2016 Sep;36(9):1646-51
pubmed: 27124882